USFDA15 Sept 2026, 06:20 pm
Aurobindo Pharma Subsidiary Completes US FDA Inspection
AI Summary
Apitoria Pharma Private Limited, a wholly owned subsidiary of Aurobindo Pharma Ltd, has successfully completed a US FDA inspection of its Unit-II API manufacturing facility in Telangana. The inspection, conducted from September 7th to September 15th, 2026, concluded with a single procedural observation. Aurobindo Pharma stated that they will respond to the US FDA within the stipulated timeline and are committed to maintaining high quality and compliance standards. Further developments will be communicated as required.
Key Highlights
- US FDA inspection of Apitoria Pharma's Unit-II facility concluded.
- Only one procedural observation was noted by the US FDA.
- Company to respond to the observation within the stipulated timeline.
- Aurobindo Pharma reaffirms commitment to quality and compliance.
Price Impact
More from AUROPHARMA